Is Merck buying TERN?
Merck entered into a definitive agreement to acquire Terns Pharmaceuticals in an all-cash transaction valued at approximately $6.7 billion. This strategic acquisition is designed to significantly expand Merck's hematology and oncology pipeline by absorbing Terns' lead clinical-stage asset, TERN-701, a promising oral treatment candidate for chronic myeloid leukemia. The purchase highlights Merck's active corporate strategy to bolster its clinical portfolio and generate diverse revenue streams ahead of upcoming patent expirations for its blockbuster cancer therapy, Keytruda.
Related FAQs
Yes, Pacific Western Bank and Banc of California completed a transformational merger on December 1, 2023.
Terumo Corporation operates with a massive global workforce of approximately thirty thousand five hundred ninety-one consolidated associates, functioning as a world-leading medical technology company.
Merck & Co. is an entirely independent, publicly traded American multinational pharmaceutical corporation listed on the New York Stock Exchange and is not owned by Bayer.